Keymed Biosciences Co.ltd

This study tests a new biologic drug, CM518D1, in people with advanced solid tumors that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors. About 434 par…

This Phase 2 trial tests an injectable biologic called CM512 in 48 adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines. Participants are randomly assigned to receive either CM512 or a placebo shot, an…

This study tests an experimental drug called CM336 in people with relapsed or refractory autoimmune cytopenia, including ITP and autoimmune hemolytic anemia. CM336 is a bispecific antibody designed to target and eliminate certain immune cells. The trial will enroll 158 adults to …

This study tests an experimental drug called CM336 in 90 adults whose primary light-chain amyloidosis has come back or not responded to prior treatments. The drug is designed to help the immune system attack the abnormal cells causing the disease. The main goal is to see how many…

This study looks at the long-term safety and effectiveness of a drug called CM512 for people with atopic dermatitis (eczema). It is for patients who have already finished a previous CM512 study. The main goal is to track any side effects over time.

This early-stage study tests a new drug, CM383, in 30 healthy adult men. The goal is to see how the drug moves through the body and check for side effects. Participants receive a single dose either by injection under the skin or into a vein. This study does not aim to treat any d…

This early-stage study tests whether a new drug, CM559, is safe and how the body processes it. About 40 healthy men will receive either the drug or a placebo. The goal is to check for side effects and understand how the drug behaves, not to treat any disease.